Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTA-C585 in RSV Challenge Model
NCT02718937Phase 2Completed
- Sponsor
- Biota Holdings Limited
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing BTA-C585 with Placebo (2 arms). Primary endpoint: Area under the curve (AUC) viral load of RSV-A Memphis 37b. Started Mar 2016; status: completed.
02
Drugs
enzaplatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02718937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718937.